Author

Mark Watling

Observed names: M. Watling, Watling, Mark

Observed institutions: University of Nottingham, Gabrail Cancer Center, Novo Nordisk (United Kingdom), UCB Pharma (United Kingdom), UCB Pharma (Belgium)

ORCID: 0000-0001-6855-6222

Observed ORCID: 0000-0001-6855-6222

OpenAlex ID: A5001163013

A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

2021 · Bruno P. Imbimbo, Stefania Ippati, et al. · Alzheimer s & Dementia · 75

Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies

2022 · Bruno P. Imbimbo, Stefania Ippati, et al. · Pharmacological Research · 66

PDF

Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 µg in healthy volunteers

2010 · A. Fisher, M. Watling, et al. · International Journal of Clinical Pharmacology and Therapeutics · 65

Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188

2010 · A. Fisher, M. Watling, et al. · International Journal of Clinical Pharmacology and Therapeutics · 62

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story

2022 · BrunoP Imbimbo, Claudia Balducci, et al. · Neural Regeneration Research · 61

Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study*

2021 · R. Oliver, J.G. Krueger, et al. · British Journal of Dermatology · 53

PDF

Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives

2020 · Bruno P. Imbimbo, Madia Lozupone, et al. · Expert Opinion on Investigational Drugs · 31

Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?

2022 · Filomena Lo Vecchio, Paola Bisceglia, et al. · Therapeutic Advances in Chronic Disease · 28

PDF

Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?

2022 · Madia Lozupone, Bruno Pietro Imbimbo, et al. · Alzheimer s & Dementia · 25

Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere?

2020 · Bruno Pietro Imbimbo, Stefania Ippati, et al. · Expert Opinion on Drug Discovery · 19

Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?

2020 · Bruno P. Imbimbo, Stefania Ippati, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 16

PDF

Clinical Bridging Studies and Modeling Approach for Implementation of a Patient Centric Sampling Technique in Padsevonil Clinical Development

2023 · Hester Kramer, Ceyhun Bicer, et al. · The AAPS Journal · 6

PDF

The European Acquired Haemophilia Registry

2004 · Mark Watling · Blood Coagulation & Fibrinolysis · 4

Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism

2020 · Francesco Panza, Madia Lozupone, et al. · Expert Opinion on Pharmacotherapy · 3

Efficacy and safety of fentanyl pectin nasal spray versus immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain.

2010 · M. T. Fallon, A. Davies, et al. · Journal of Clinical Oncology · 3

Fentanyl pectin nasal spray (FPNS) with PecSys® provides most favorable pharmacokinetic/tolerability profile compared with nasal chitosan-based fentanyl and oral transmucosal fentanyl citrate (OTFC)

2009 · T. Fisher, A. Knight, et al. · Journal of Pain · 2

PDF

Pharmacokinetic and local tolerability profiles of three potential fentanyl nasal spray formulations developed for breakthrough cancer pain compared with oral transmucosal fentanyl citrate

2009 · D. R. Taylor, A. N. Fisher, et al. · Journal of Clinical Oncology

Works count: 18

Citation count: 519

H-index: 11

I10-index: 11